The strategic incorporation of halogens, particularly bromine, into organic molecules has long been a cornerstone of medicinal chemistry. Halogenation can profoundly influence a compound's physical properties, metabolic stability, lipophilicity, and binding affinity to biological targets, thereby enhancing its therapeutic potential. This principle holds true for pharmaceutical intermediates, where the presence of a halogen atom can unlock new synthetic possibilities and lead to more effective drug candidates. One such pivotal intermediate is 7-Bromo-2-methyl-1-indanone (CAS 213381-43-2).

Halogens as Modifiers of Biological Activity
Halogen atoms, due to their electronegativity and size, can significantly alter the electronic distribution within a molecule. Bromine, being larger and more polarizable than chlorine or fluorine, often plays a crucial role in mediating intermolecular interactions, such as halogen bonding, which is increasingly recognized for its importance in drug-target recognition. Furthermore, the introduction of a halogen atom can modulate a molecule's lipophilicity, impacting its absorption, distribution, metabolism, and excretion (ADME) profile. This can lead to improved oral bioavailability, enhanced membrane permeability, and increased resistance to metabolic degradation.

7-Bromo-2-methyl-1-indanone: A Halogenated Building Block of Value
As a key pharmaceutical intermediate, 7-Bromo-2-methyl-1-indanone embodies the advantages of halogenated structures. Its bromine atom, positioned at the 7-position of the indanone ring, is strategically located to influence both the reactivity of the molecule and the properties of its derivatives. This makes it an excellent candidate for further functionalization via various synthetic routes, including palladium-catalyzed cross-coupling reactions. These reactions allow for the introduction of diverse pharmacophores, enabling medicinal chemists to fine-tune the biological activity of potential drug candidates.

From Intermediate to API: A Seamless Process
The journey from a chemical intermediate to a final API often involves complex synthetic pathways. The reliability and quality of the starting materials are paramount. As a leading manufacturer and supplier of pharmaceutical intermediates in China, we specialize in providing high-purity compounds like 7-Bromo-2-methyl-1-indanone (CAS 213381-43-2). Our expertise ensures that this intermediate is produced with stringent quality controls, allowing researchers and manufacturers to confidently integrate it into their synthesis protocols. By choosing to buy from us, you ensure that your critical building block contributes positively to your drug discovery and development pipeline.

Impact on Drug Discovery and Development
The availability of well-characterized and high-quality halogenated intermediates like 7-Bromo-2-methyl-1-indanone facilitates rapid exploration of chemical space. Medicinal chemists can systematically modify this intermediate to generate libraries of compounds that can be screened for therapeutic potential against various disease targets. The bromine atom provides a reliable handle for SAR (Structure-Activity Relationship) studies, helping researchers understand how structural modifications impact biological activity. This iterative process of synthesis, testing, and refinement is fundamental to modern drug discovery.

Conclusion
Halogenated intermediates are indispensable tools in modern medicinal chemistry and drug discovery. 7-Bromo-2-methyl-1-indanone (CAS 213381-43-2) exemplifies the value of such compounds, offering unique synthetic flexibility and contributing to the development of novel therapeutics. Partnering with a trusted manufacturer ensures access to this vital intermediate, empowering innovation in pharmaceutical R&D.